Adamant Biomedical Investments’s Ligand Pharmaceuticals LGND Stock Holding History

Adamant Biomedical Investments’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	$4.33M	Buy	+130,292	New	+$4.24M	1.03%	35

Other funds holding LGND

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adamant Biomedical Investments's LGND Position: Q4 2014 in Review

Adamant Biomedical Investments opened a new position in Ligand Pharmaceuticals (LGND) in Q4 2014: 130,292 shares worth $4.33M. The stake represents 1.03% of the portfolio and ranks #35 among its holdings.

180 funds tracked by Wall St. Rank hold LGND as of Q4 2014.

Adamant Biomedical Investments held 130,292 shares of Ligand Pharmaceuticals worth $4.33M as of Q4 2014.
Ligand Pharmaceuticals was a new Adamant Biomedical Investments position in Q4 2014.
Ligand Pharmaceuticals made up 1.03% of Adamant Biomedical Investments's portfolio in Q4 2014, its #35 holding.
180 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.